EXAM SERIES
NURS 6521 Advanced
Pharmacology —
Midterm Exam
Comprehensive Exam — Questions and Answers
105 Questions
with Answers and Complete Rationales
01 NURS 6521 midterm content: pharmacokinetics, pharmacogenomics,
drug interactions, anti-infectives, cardiovascular, CNS, endocrine, and
special populations
02 Answers with explanatory rationales
03 Organized by pharmacologic principles and clinical application
04 Complete questions and answers
2026 EDITION
Questions and Answers • Complete Rationales
, Exam Instructions
This examination is a custom-length multiple-choice simulation containing 105 questions organized
into eight content sections. The 105-question count is a custom length and does not represent the
official Walden University NURS 6521 Midterm Exam length, which is not publicly specified. This
document is an independently authored review resource and is not affiliated with, endorsed by, or
representative of any official Walden University assessment, its secure item pool, or its operational
delivery platform.
Each question has four options labeled A through D and exactly one best answer. The correct
answer and a concise rationale follow each question. Read each stem carefully, noting patient age,
comorbidities, concurrent medications, and laboratory values before selecting a response. Select
the single best option; more than one option may appear partially correct, but only one is the most
complete and accurate answer.
Section 1: Pharmacokinetics and Pharmacodynamics
Q1–Q16 — Absorption, distribution, metabolism, excretion, first-pass effect, bioavailability, half-life, steady state,
protein binding, volume of distribution, loading dose, and therapeutic index.
Q1. A patient is prescribed nitroglycerin sublingual tablets for acute angina episodes. What is the
primary pharmacokinetic rationale for the sublingual route of administration?
A. It increases drug binding to plasma proteins and prolongs action.
B. It relies on gastric acidity to convert the drug to its active form.
C. It saturates P-glycoprotein efflux in the intestinal wall.
D. It bypasses hepatic first-pass metabolism, producing rapid therapeutic effect.
Correct Answer: D. It bypasses hepatic first-pass metabolism, producing rapid therapeutic effect.
Sublingual nitroglycerin is absorbed through the rich oral venous plexus and enters the systemic
circulation directly, avoiding initial passage through the liver where extensive first-pass metabolism
would otherwise inactivate most of the dose. This produces rapid onset (within minutes) appropriate for
acute angina. Oral nitroglycerin would be largely inactivated before reaching target vessels. Protein
binding, gastric acidity, and P-glycoprotein are not the principal reasons for choosing the sublingual
route.
,Q2. Which statement most accurately defines the bioavailability of an orally administered drug?
A. The rate at which the drug distributes into adipose tissue.
B. The percentage of the dose that reaches the systemic circulation unchanged.
C. The total quantity of drug metabolized by hepatic enzymes per hour.
D. The degree to which the drug binds serum albumin.
Correct Answer: B. The percentage of the dose that reaches the systemic circulation unchanged.
Bioavailability is the fraction of an administered dose that reaches the systemic circulation in an active
form. For intravenous drugs, bioavailability is 100%. For oral drugs, bioavailability is reduced by
incomplete absorption and hepatic first-pass metabolism. Distribution into tissues, metabolic rate, and
protein binding are distinct pharmacokinetic parameters that do not define bioavailability.
Q3. A drug has a half-life of 8 hours and is administered on a fixed schedule. Approximately how
long will it take to reach steady-state plasma concentrations in a patient with normal hepatic and
renal function?
A. 8 hours
B. 16 hours
C. 40 hours
D. 24 hours
Correct Answer: C. 40 hours
Steady state is reached after approximately 4 to 5 half-lives of continuous dosing. With a half-life of 8
hours, 5 half-lives equal 40 hours (about 1.7 days). At steady state, the amount of drug administered
per dosing interval equals the amount eliminated. Eight hours is one half-life, 16 hours is two, and 24
hours is three — all insufficient for steady state.
Q4. A 68-year-old patient taking warfarin 5 mg daily is started on sulfamethoxazole-trimethoprim
for a urinary tract infection. One week later, the INR is 6.2 and the patient reports gingival
bleeding. Which pharmacokinetic and pharmacodynamic mechanism best explains this
interaction?
A. Sulfamethoxazole induces CYP2C9, accelerating warfarin clearance.
B. Sulfamethoxazole displaces warfarin from albumin and induces CYP2C9 simultaneously.
C. Sulfamethoxazole inhibits CYP2C9, reducing warfarin metabolism and increasing INR.
D. Sulfamethoxazole increases gastric pH and enhances warfarin absorption.
Correct Answer: C. Sulfamethoxazole inhibits CYP2C9, reducing warfarin metabolism and
increasing INR.
Trimethoprim-sulfamethoxazole inhibits CYP2C9, the primary enzyme metabolizing the more potent S-
enantiomer of warfarin. Inhibition reduces clearance, raises plasma warfarin levels, prolongs the INR,
and increases bleeding risk. The interaction is metabolic (CYP inhibition), not induction or absorption-
related. While protein-binding displacement can transiently raise free warfarin, the dominant and
clinically significant mechanism here is CYP2C9 inhibition.
, Q5. Which patient characteristic would most likely increase the volume of distribution of a
lipophilic drug such as diazepam?
A. Severe dehydration
B. High serum albumin concentration
C. Reduced total body water
D. Increased adipose tissue mass
Correct Answer: D. Increased adipose tissue mass
Lipophilic drugs distribute extensively into adipose tissue, so increased body fat (as seen in obesity or
with aging) expands the volume of distribution and prolongs half-life. Dehydration and reduced total
body water tend to lower volume of distribution. High albumin binding sequesters drug in the vascular
compartment and reduces apparent volume of distribution rather than increasing it.
Q6. A clinician orders a loading dose of digoxin for a patient with atrial fibrillation and a rapid
ventricular response. What is the primary pharmacokinetic purpose of a loading dose?
A. To reduce the drug's therapeutic index.
B. To shorten the time required to reach therapeutic plasma concentration.
C. To increase first-pass metabolism of the drug.
D. To decrease protein binding of the drug.
Correct Answer: B. To shorten the time required to reach therapeutic plasma concentration.
For drugs with long half-lives (digoxin half-life roughly 36 to 48 hours in normal renal function),
achieving steady-state therapeutic levels through maintenance dosing alone would take several days.
A loading dose rapidly fills the volume of distribution so that effective concentrations are reached
promptly. Loading does not affect therapeutic index, first-pass metabolism, or protein binding.
Q7. Which of the following drugs is most appropriately characterized as having a narrow
therapeutic index, requiring routine serum concentration monitoring?
A. Lithium
B. Amoxicillin
C. Lisinopril
D. Acetaminophen at standard doses
Correct Answer: A. Lithium
Lithium has a narrow therapeutic index; the gap between therapeutic and toxic serum concentrations is
small, so serum levels are monitored routinely and titrated to a target range (typically 0.6 to 1.2 mEq/L
for maintenance). Amoxicillin, lisinopril, and standard-dose acetaminophen have wide therapeutic
margins and generally do not require routine serum drug monitoring in most patients.
NURS 6521 Advanced
Pharmacology —
Midterm Exam
Comprehensive Exam — Questions and Answers
105 Questions
with Answers and Complete Rationales
01 NURS 6521 midterm content: pharmacokinetics, pharmacogenomics,
drug interactions, anti-infectives, cardiovascular, CNS, endocrine, and
special populations
02 Answers with explanatory rationales
03 Organized by pharmacologic principles and clinical application
04 Complete questions and answers
2026 EDITION
Questions and Answers • Complete Rationales
, Exam Instructions
This examination is a custom-length multiple-choice simulation containing 105 questions organized
into eight content sections. The 105-question count is a custom length and does not represent the
official Walden University NURS 6521 Midterm Exam length, which is not publicly specified. This
document is an independently authored review resource and is not affiliated with, endorsed by, or
representative of any official Walden University assessment, its secure item pool, or its operational
delivery platform.
Each question has four options labeled A through D and exactly one best answer. The correct
answer and a concise rationale follow each question. Read each stem carefully, noting patient age,
comorbidities, concurrent medications, and laboratory values before selecting a response. Select
the single best option; more than one option may appear partially correct, but only one is the most
complete and accurate answer.
Section 1: Pharmacokinetics and Pharmacodynamics
Q1–Q16 — Absorption, distribution, metabolism, excretion, first-pass effect, bioavailability, half-life, steady state,
protein binding, volume of distribution, loading dose, and therapeutic index.
Q1. A patient is prescribed nitroglycerin sublingual tablets for acute angina episodes. What is the
primary pharmacokinetic rationale for the sublingual route of administration?
A. It increases drug binding to plasma proteins and prolongs action.
B. It relies on gastric acidity to convert the drug to its active form.
C. It saturates P-glycoprotein efflux in the intestinal wall.
D. It bypasses hepatic first-pass metabolism, producing rapid therapeutic effect.
Correct Answer: D. It bypasses hepatic first-pass metabolism, producing rapid therapeutic effect.
Sublingual nitroglycerin is absorbed through the rich oral venous plexus and enters the systemic
circulation directly, avoiding initial passage through the liver where extensive first-pass metabolism
would otherwise inactivate most of the dose. This produces rapid onset (within minutes) appropriate for
acute angina. Oral nitroglycerin would be largely inactivated before reaching target vessels. Protein
binding, gastric acidity, and P-glycoprotein are not the principal reasons for choosing the sublingual
route.
,Q2. Which statement most accurately defines the bioavailability of an orally administered drug?
A. The rate at which the drug distributes into adipose tissue.
B. The percentage of the dose that reaches the systemic circulation unchanged.
C. The total quantity of drug metabolized by hepatic enzymes per hour.
D. The degree to which the drug binds serum albumin.
Correct Answer: B. The percentage of the dose that reaches the systemic circulation unchanged.
Bioavailability is the fraction of an administered dose that reaches the systemic circulation in an active
form. For intravenous drugs, bioavailability is 100%. For oral drugs, bioavailability is reduced by
incomplete absorption and hepatic first-pass metabolism. Distribution into tissues, metabolic rate, and
protein binding are distinct pharmacokinetic parameters that do not define bioavailability.
Q3. A drug has a half-life of 8 hours and is administered on a fixed schedule. Approximately how
long will it take to reach steady-state plasma concentrations in a patient with normal hepatic and
renal function?
A. 8 hours
B. 16 hours
C. 40 hours
D. 24 hours
Correct Answer: C. 40 hours
Steady state is reached after approximately 4 to 5 half-lives of continuous dosing. With a half-life of 8
hours, 5 half-lives equal 40 hours (about 1.7 days). At steady state, the amount of drug administered
per dosing interval equals the amount eliminated. Eight hours is one half-life, 16 hours is two, and 24
hours is three — all insufficient for steady state.
Q4. A 68-year-old patient taking warfarin 5 mg daily is started on sulfamethoxazole-trimethoprim
for a urinary tract infection. One week later, the INR is 6.2 and the patient reports gingival
bleeding. Which pharmacokinetic and pharmacodynamic mechanism best explains this
interaction?
A. Sulfamethoxazole induces CYP2C9, accelerating warfarin clearance.
B. Sulfamethoxazole displaces warfarin from albumin and induces CYP2C9 simultaneously.
C. Sulfamethoxazole inhibits CYP2C9, reducing warfarin metabolism and increasing INR.
D. Sulfamethoxazole increases gastric pH and enhances warfarin absorption.
Correct Answer: C. Sulfamethoxazole inhibits CYP2C9, reducing warfarin metabolism and
increasing INR.
Trimethoprim-sulfamethoxazole inhibits CYP2C9, the primary enzyme metabolizing the more potent S-
enantiomer of warfarin. Inhibition reduces clearance, raises plasma warfarin levels, prolongs the INR,
and increases bleeding risk. The interaction is metabolic (CYP inhibition), not induction or absorption-
related. While protein-binding displacement can transiently raise free warfarin, the dominant and
clinically significant mechanism here is CYP2C9 inhibition.
, Q5. Which patient characteristic would most likely increase the volume of distribution of a
lipophilic drug such as diazepam?
A. Severe dehydration
B. High serum albumin concentration
C. Reduced total body water
D. Increased adipose tissue mass
Correct Answer: D. Increased adipose tissue mass
Lipophilic drugs distribute extensively into adipose tissue, so increased body fat (as seen in obesity or
with aging) expands the volume of distribution and prolongs half-life. Dehydration and reduced total
body water tend to lower volume of distribution. High albumin binding sequesters drug in the vascular
compartment and reduces apparent volume of distribution rather than increasing it.
Q6. A clinician orders a loading dose of digoxin for a patient with atrial fibrillation and a rapid
ventricular response. What is the primary pharmacokinetic purpose of a loading dose?
A. To reduce the drug's therapeutic index.
B. To shorten the time required to reach therapeutic plasma concentration.
C. To increase first-pass metabolism of the drug.
D. To decrease protein binding of the drug.
Correct Answer: B. To shorten the time required to reach therapeutic plasma concentration.
For drugs with long half-lives (digoxin half-life roughly 36 to 48 hours in normal renal function),
achieving steady-state therapeutic levels through maintenance dosing alone would take several days.
A loading dose rapidly fills the volume of distribution so that effective concentrations are reached
promptly. Loading does not affect therapeutic index, first-pass metabolism, or protein binding.
Q7. Which of the following drugs is most appropriately characterized as having a narrow
therapeutic index, requiring routine serum concentration monitoring?
A. Lithium
B. Amoxicillin
C. Lisinopril
D. Acetaminophen at standard doses
Correct Answer: A. Lithium
Lithium has a narrow therapeutic index; the gap between therapeutic and toxic serum concentrations is
small, so serum levels are monitored routinely and titrated to a target range (typically 0.6 to 1.2 mEq/L
for maintenance). Amoxicillin, lisinopril, and standard-dose acetaminophen have wide therapeutic
margins and generally do not require routine serum drug monitoring in most patients.
